The delivery system developed at Western uses bacteria’s natural ability to replicate – called bacterial conjugation – to deliver CRISPR to specific bacteria, in order to alter its DNA and kill it.
Researchers at Western University have developed a new way to deliver the DNA-editing tool CRISPR-Cas9 into microorganisms in the lab, providing a way to efficiently launch a targeted attack on specific bacteria.
Published today in Nature Communications, this study opens up the possibility of using CRISPR to alter the makeup of the human microbiome in a way that could be personalized and specific from person to person. It also presents a potential alternative to traditional antibiotics to kill bacteria like Staphyloccous aureus (Staph A) or Escherichia coli (E. coli).
“One of the major reasons that I am excited about this work is that it has a wide range of possible real-world applications,” said Bogumil Karas, PhD, Assistant Professor at Western’s Schulich School of Medicine & Dentistry. “It has the potential for development of next generation antimicrobial agents that would be effective even for bacteria that are resistant to all known antibiotics. This technology could also be used to help ‘good’ bacteria produce compounds to treat diseases caused by protein deficiencies.”
CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats and can be programmed to target specific stretches of genetic code and to edit DNA at precise locations. Researchers use CRISPR to permanently modify genes in living cells and organisms.
In this way, CRISPR can be programmed to kill bacteria, but until now there wasn’t a way to efficiently and specifically target certain bacterial strains.
“Using CRISPR to kill things isn’t a new idea because that’s what CRISPR does naturally,” said David Edgell, PhD, Professor at Schulich Medicine & Dentistry. “The problem has always been how you get CRISPR to where you want it to go. Other delivery systems could only go to a few spots, where ours can go anywhere.”
The delivery system developed at Western uses bacteria’s natural ability to replicate – called bacterial conjugation – to deliver CRISPR to specific bacteria, in order to alter its DNA and kill it.
“Specific delivery of any therapeutic agent, including CRISPR, is usually one of the biggest bottlenecks in development of new treatments. By developing this new delivery system, we created new tools that could help us in the development of more effective therapies in the near future,” said Karas.
The team says their delivery system is not only broadly applicable, but it is also more efficient than previous systems.
“We were able to show near complete transfer of the delivery vehicle to another bacterial species under conditions where they are in intimate contact – in a biofilm. This is important because biofilms are the natural state of the majority of bacteria, and being able to transfer DNA under these conditions is typically difficult, but we found a way to make it easy and efficient,” said Gregory Gloor, PhD, Professor at Schulich Medicine & Dentistry.
Learn more: Researchers unlock potential to use CRISPR to alter the microbiome
The Latest on: Next generation antimicrobial agents
via Google News
The Latest on: Next generation antimicrobial agents
- Wound Dressing Market Size Worth $16.24 Billion by 2028 at 6.2% CAGR Lead by Advanced Wound Dressings, New Research Study by The Insight Partnerson June 23, 2022 at 5:34 am
In February 2021, Axio Biosolutions announced that its next ... antimicrobial dressings are currently being used as an alternative to traditional dressings and systemic antibiotics. Antimicrobial ...
- Tackling Respiratory Infections in the 21st Centuryon June 22, 2022 at 7:15 am
The encroachment of human activity and dwellings into the habitat of wild creatures has increased the risk of spillover of viruses, bacteria, fungi, and protozoal infections into humans.
- The Role of Antimicrobial Silver Nanotechnologyon June 14, 2022 at 5:00 pm
However, manufacturers are faced with identifying which antimicrobial agent will be effective against a wide range of organisms and yet will be tolerated next to healthy tissue ... critical function ...
- Hospital Rules-Based System: The Next Generation of Medical Informatics for Patient Safetyon June 10, 2022 at 4:59 pm
The CPIDD subsystem is modeled closely after the CBAM and has three primary objectives: (1) enhancing the efficiency and quality of infectious-diseases consultations, (2) improving the continuity ...
- Nosopharm, GNA NOW announce positive results for late preclinical development of first-in-class antibiotic NOSO-502on June 10, 2022 at 5:30 am
Nosopharm, GNA NOW announce positive results for late preclinical development of first-in-class antibiotic NOSO-502: Utrecht, the Netherlands Friday, June 10, 2022, 18:00 Hrs [IST ...
- Clariant expands pre-approved line of additives, masterbatches for medicalon June 2, 2022 at 5:00 pm
MedX antimicrobial agents: additive packages using antimicrobial ... In addition, the company introduced what it called productivity-enhancing additives: Next generation nucleants and process aids: ...
- Oxford Finance Announces the Closing of a $30 Million Credit Facility With Selux Diagnosticson June 1, 2022 at 7:03 am
Funding will support the commercial launch of Selux’s Next-Generation Phenotyping rapid antimicrobial susceptibility testing ... epidemic by decreasing the overuse of broad-spectrum agents. The 5-year ...
- Oxford Finance Announces the Closing of a $30...on June 1, 2022 at 6:27 am
Proceeds from the transaction will fund the commercialization of the Company's Next-Generation Phenotyping ("NGP") rapid antimicrobial ... overuse of broad-spectrum agents. The 5-year-old company ...
- Clinical Relevance of the ESKAPE Pathogenson May 31, 2022 at 5:00 pm
In the pursuit of next-generation antibiotics, selection should be directed towards agents showing antibiofilm activity. The antimicrobial 'pipeline' is showing early signs of resurgence ...
- After COVID-19, our next big health care challenge will be drug-resistant infectionson May 25, 2022 at 8:25 am
It’s called “antimicrobial resistance” (AMR ... of the antibiotics we have and give us the time to enable the development of the next generation of antibiotics. One lesson that we all have learned ...
via Bing News